pcn poster

Posters

Extended-Release Viloxazine (SPN-812) 100 mg or 200 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-defic...

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Stefan Schwabe , MD, PhD;

11/22/2019

Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil With 1-Day Initiation in Acutely Ill Patients With Schizophrenia

Objective: Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia. ...

Sergey Yagoda , PhD, MD;

David Walling , PhD, CNS, MD;

Jelena Kunovac , MD;

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

11/22/2019

Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

Depression occurs in ~50% of Parkinson’s disease (PD) patients, increases in severity as the disease progresses, and is associated with increased morbidity. We are assessing use of pimava...

Daryl DeKarske , MPH;

Bruce Coate , MPH;

James C. Norton , PhD;

Michael Guskey , PharmD;

Gustavo Alva , MD, DFAAPA;

Jason Aldred , MD, FAAN;

Marc Cantillon , MD;

11/22/2019

Effects of Cariprazine on Prolactin Levels in Patients With Bipolar I Disorder

Background: Antipsychotic treatment has been linked to hyperprolactinemia, which can lead to increased nonadherence and changes in sexual hormones in both men and women. Here, we evaluate...

Mehul Patel , MD, PharmD;

Larry Culpepper , MD;

Deanna Kelly ;

Eduard Vieta , MD, PhD;

Thais Moreira , PharmD, PhD;

Willie Earley , MD;

11/22/2019

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

Craig Nelson , MD;

Carmine Rossi , PhD;

Ella Daly , MB, BCh, BAO;

Maryia Zhdanava , MA;

Harsh Kuvadia ;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

11/22/2019

Assessment of Health-Related Quality of Life and Health Status in Patients With Treatment Resistant Depression Treated With Esketamine Nasal Spray Plus Oral Antidepressant Using European Quality of Life Group-5-Dimension-5-Level

Objective: To assess health-related quality of life (HRQoL) and health status of patients with treatment resistant depression (TRD), treated with esketamine nasal spray+oral antidepressan...

Vanina Popova , MD;

Ella Daly , MB, BCh, BAO;

Kimberly Cooper , MS;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

11/22/2019

Efficacy and Safety of a Delayed-Release and Extended-Release Methylphenidate Formulation in Children With ADHD: Results From a Pivotal Phase 3 Trial in a Naturalistic Setting

Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into...

Steven Pliszka , MD;

Jeffrey Newcorn , MD;

Samantha Bostrom , MD;

Frank López , MD;

Andrea Marraffino , PhD;

Norberto DeSousa , MA;

Bev Incledon , PhD;

F. Randy Sallee , MD, PhD;

Andrew J. Cutler , MD;

Valerie Arnold , MD;

Timothy Wilens , MD;

11/22/2019

Post Hoc Analyses of Remission From 2 Studies of SHP465 Mixed Amphetamine Salts Extended-Release in Adults With Attention-Deficit/Hyperactivity Disorder

In adults with attention-deficit/hyperactivity disorder (ADHD), reductions in ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) were significantly greater with SHP465 mixed amphetamine sal...

Brigitte Robertson , MD;

Lenard Adler , MD;

Elias Sarkis , MD;

Richard Able , PhD;

Jie Chen , MS;

11/22/2019

Reframing the Approach to the Diagnosis and Treatment of Borderline Personality Disorder in Adolescents

Using the same DSM-5 diagnostic criteria for Borderline Personality Disorder (BPD) as in adults, but only requiring a 1 year duration, adolescents as young as 13, with a pattern of immatu...

Daniel Matthews ;

11/22/2019

Patient-Centric Outcomes Among Patients With Major Depressive Disorder: Comparisons Across Depression Severity

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: Patient Health Questionnaire-9 (PHQ-9) is a validated patient self-ad...

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products